Strategy for measles eradication

Rinderpest and Peste des Petits Ruminants

Volumn , Issue , 2006, Pages 284-297

  Rima, Bertus K ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882505578     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088385-1/50044-7     Document Type: Chapter

References (26)

1. Bellanti J.A., Zeligs B.J., et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with meales vaccine. Vaccine 2004, 22(9-10):1214-1220.
2. de Quadros C.A. Can measles be eradicated globally?. Bull. WHO 2004, 82(2):134-138.
3. El Kasmi K.C., Fillon S., et al. Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies. J. Gen. Virol. 2000, 81:729-735. (Pt 3).
4. El Mubarak H.S., Ibrahim S.A., et al. Measles virus protein-specific IgM, IgA, and IgG subclass responses during the acute and convalescent phase of infection. J. Med. Virol. 2004, 72(2):290-298.
5. Fooks A.R., Jeevarajah D., et al. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. J. Gen. Virol. 1998, 79:1027-1031.
6. Griffin D., Bellini W.J. Measles virus. Fields Virology 2001, 1401-1442. Lippincott-Williams & Wilkins, Philadelphia. 4th edn. D.M. Knipe (Ed.).
7. Haynes L.M., Jones L.P., et al. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. 2003, 77(18):9831-9844.
8. Kuroiwa C., Xayyavong P., et al. Difficulties in measles elimination: prevalence of meales antibodies before and after mass vaccination campaign in Laos. Vaccine 2003, 21(5-6):479-484.
9. Naniche D., Yeh A., et al. Evasion of host defenses by measles virus: wild-type meales virus infection interferes with induction of Alpha/Beta interferon production. J. Virol. 2000, 74(16):7478-7484.
10. Pabst H.F., Spady D.W., et al. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 1999, 17(15-16):1910-1918.
11. Polack F.P., Auwaerter P.G., et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 1999, 5(6):629-634.
12. Polack F.P., Hoffman S.J., et al. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 2003, 9(9):1209-1213.
13. Polack F.P., Hoffman S.J., et al. Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J. Infect. Dis. 2003, 187(11):1794-1800.
14. Polack F.P., Lee S.H., et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 2000, 6(7):776-781.
15. Prince G.A., Mond J.J., et al. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. 2003, 77(24):13156-13160.
16. Pütz M.M., Muller C.P. The rationale of a peptide-conjugate vaccine against measles. Vaccine 2002, 21(7-8):663-666.
17. Pütz M.M., Bouche F.B., de Swart R.L., Muller C.P. Experimental vaccines against measles in a world of changing epidemiology. Int. J. Parsitol. 2003, 33(5-6):525-545.
18. Rima B. Measles virus. Encyclopedia of the Life Sciences (CD ROM only) 1999, Article number 418, MR Ltd, Stockton Press.
19. Sepulveda-Amor J., Valdespino-Gomez J.L., et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002, 20(21-22):2790-2795.
20. Sharpe S., Fooks A., et al. Single oral immunization with replication-deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology 2002, 293(2):210-216.
21. Skiadopoulos M.H., Surman S.R., et al. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J. Virol. 2001, 75(21):10498-10504.
22. Tatsuo H., Yanagi Y. The morbillivirus receptor SLAM (CD150). Microbiol. Immunol. 2002, 46(3):135-142.
23. van Binnendijk R.S., Poelen M.C., et al. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 1997, 175(3):524-532.
24. Varsanyi T.M., Morein B., et al. Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein. J. Virol. 1987, 61(12):3896-3901.
25. Wyde P.R., Stittelaar K.J., et al. Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine 2000, 19(1):42-53.
26. Zhu Y., Rota P., et al. Evaluation of recombinant vaccinia virus-measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 2000, 276(1):202-213.